Skip to main content
OpenTrials
Completed

NCT Number: NCT04068844

Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction

The global objective of this study is to determine the mechanisms of exercise intolerance and dyspnea on exertion (DOE) in patients with HFpEF and based on this pathophysiology, test whether specific exercise training programs (whole body vs single leg) will result in improved exercise tolerance.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Institute for Exercise and Environmental Medicine

Dallas, Texas, 75231, United States

About this study

This will be a randomized, non-blinded prospective intervention testing the effects of two types of exercise training, whole body and isolated single leg, on HFpEF patients with either central or peripheral limitations to exercise training. Subjects will undergo baseline maximal exercise testing and invasive right heart catheterization to define exercise tolerance and pulmonary and cardiac pressures during exercise. Based on the results of baseline testing, subjects will be divided into either centrally limited, defined as excessive rise in pulmonary capillary wedge pressure more than 25 mmHg that decreases after administration of sub-lingual nitroglycerin resulting in improved exercise tolerance, or peripherally limited, defined as no improvement in exercise tolerance despite reduction in pulmonary capillary wedge pressure after sublingual nitroglycerin. After baseline testing, subjects will be randomized to either whole body cycle exercise supplemented with sublingual nitroglycerin to improve training responsiveness or isolated single leg exercise training for 4 months. After 4 months, subjects will repeat maximal exercise testing and invasive right heart catheterization to assess responses to 4 months of exercise training.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • signs and symptoms of heart failure
  • an ejection fraction > 0.50
  • objective evidence of diastolic dysfunction

Exclusion criteria

  • age < 60 years
  • BMI > 50 kg/m2
  • PDE5 inhibitor use
  • Severe valvular disease
  • Severe COPD
  • CKD 4 or higher
  • Contra-indication to MRI.

Treatment and study plan

Exercise Training

Behavioral

Exercise training, either whole body or isolated single leg

Primary outcomes

  1. Aerobic fitness

    Time frame: 4 months

    Change in peak VO2 after exercise training

Secondary outcomes

  1. Cardiopulmonary hemodynamics

    Time frame: 4 months

    Change in exercise pulmonary capillary wedge pressure

  2. Sympathetic activity

    Time frame: 4 months

    Change in muscle sympathetic activity

  3. Leg blood flow

    Time frame: 4 months

    Change in leg blood flow assessed by Doppler velocities in femoral artery

  4. Cardiac fibrosis

    Time frame: 4 months

    Change in T1 mapping times by cardiac MRI

Sponsors and collaborators

Lead sponsor

University of Texas Southwestern Medical Center

Other

Collaborators

  • The University of Texas at Arlington

Registry information

Important dates

Study start
2019
Primary completion
2025
Study completion
2026
First posted
Aug 28, 2019
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.